| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial intelligence (AI) | 73.06 | 148 |
| Intrinsic value (DCF) | 2675.81 | 8992 |
| Graham-Dodd Method | 2.34 | -92 |
| Graham Formula | 7.59 | -74 |
TG Therapeutics, Inc. (NASDAQ: TGTX) is a commercial-stage biopharmaceutical company specializing in innovative therapies for B-cell malignancies and autoimmune diseases. Headquartered in New York, the company focuses on developing and commercializing novel treatments, including Ublituximab (a glycoengineered monoclonal antibody for B-cell cancers and multiple sclerosis) and Umbralisib (a dual PI3K-delta/CK1-epsilon inhibitor for hematologic malignancies). TG Therapeutics also has a promising pipeline featuring Cosibelimab (a PD-L1 inhibitor), TG-1701 (a selective BTK inhibitor), and TG-1801 (a bispecific CD47/CD19 antibody). With strategic collaborations with Checkpoint Therapeutics, Novimmune, and others, TG Therapeutics is positioned as a key player in oncology and autoimmune therapeutics. The company’s focus on precision medicine and targeted therapies aligns with growing demand for next-generation treatments in hematologic cancers and immune disorders.
TG Therapeutics presents a high-risk, high-reward investment opportunity due to its niche focus on B-cell malignancies and autoimmune diseases. The company’s recent commercialization of Ublituximab (Briumvi) for multiple sclerosis and its expanding oncology pipeline offer growth potential, but competition in the BTK and CD19/CD47 inhibitor space is intense. Financials show modest revenue ($329M in FY2024) and profitability ($23.4M net income), but operating cash flow remains negative (-$40.5M), reflecting R&D-heavy spending. With a beta of 2.2, TGTX is highly volatile, appealing to speculative investors betting on clinical successes. Key risks include pipeline setbacks, reimbursement challenges, and competition from larger biopharma players.
TG Therapeutics competes in the crowded BTK inhibitor and CD20-targeted therapy markets, where differentiation is critical. Its lead asset, Ublituximab, competes with Roche’s Rituxan and Gazyva, as well as Novartis’ Kesimpta in multiple sclerosis. While Ublituximab’s glycoengineering may offer efficacy advantages, it faces entrenched competitors with established market share. Umbralisib’s PI3K-delta inhibition puts it in direct competition with Gilead’s Zydelig and BeiGene’s Brukinsa, though safety concerns in the PI3K class could limit adoption. TG-1701 (BTK inhibitor) must differentiate against AbbVie’s Imbruvica and AstraZeneca’s Calquence, which dominate the CLL market. The company’s bispecific CD47/CD19 antibody (TG-1801) could carve a niche in hematologic cancers, but it trails behind Gilead’s magrolimab and other CD47 inhibitors. TG’s partnerships (e.g., with LFB Biotechnologies) provide manufacturing leverage, but its small scale compared to rivals like Roche or AbbVie limits commercialization reach. Success hinges on clinical differentiation and targeted indications with unmet needs.